↓ Skip to main content

Sorafenib prevents liver fibrosis in a non-alcoholic steatohepatitis (NASH) rodent model

Overview of attention for article published in Brazilian Journal of Medical and Biological Research, May 2015
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
1 X user

Citations

dimensions_citation
21 Dimensions

Readers on

mendeley
50 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Sorafenib prevents liver fibrosis in a non-alcoholic steatohepatitis (NASH) rodent model
Published in
Brazilian Journal of Medical and Biological Research, May 2015
DOI 10.1590/1414-431x20143962
Pubmed ID
Authors

J.T. Stefano, I.V.A. Pereira, M.M. Torres, P.M. Bida, A.M.M. Coelho, M.P. Xerfan, B. Cogliati, D.F. Barbeiro, D.F.C. Mazo, M.S. Kubrusly, L.A.C. D'Albuquerque, H.P. Souza, F.J. Carrilho, C.P. Oliveira

Abstract

Liver fibrosis occurring as an outcome of non-alcoholic steatohepatitis (NASH) can precede the development of cirrhosis. We investigated the effects of sorafenib in preventing liver fibrosis in a rodent model of NASH. Adult Sprague-Dawley rats were fed a choline-deficient high-fat diet and exposed to diethylnitrosamine for 6 weeks. The NASH group (n=10) received vehicle and the sorafenib group (n=10) received 2.5 mg·kg-1·day-1 by gavage. A control group (n=4) received only standard diet and vehicle. Following treatment, animals were sacrificed and liver tissue was collected for histologic examination, mRNA isolation, and analysis of mitochondrial function. Genes related to fibrosis (MMP9, TIMP1, TIMP2), oxidative stress (HSP60, HSP90, GST), and mitochondrial biogenesis (PGC1α) were evaluated by real-time quantitative polymerase chain reaction (RT-qPCR). Liver mitochondrial oxidation activity was measured by a polarographic method, and cytokines by enzyme-linked immunosorbent assay (ELISA). Sorafenib treatment restored mitochondrial function and reduced collagen deposition by nearly 63% compared to the NASH group. Sorafenib upregulated PGC1α and MMP9 and reduced TIMP1 and TIMP2 mRNA and IL-6 and IL-10 protein expression. There were no differences in HSP60, HSP90 and GST expression. Sorafenib modulated PGC1α expression, improved mitochondrial respiration and prevented collagen deposition. It may, therefore, be useful in the treatment of liver fibrosis in NASH.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 50 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Belgium 1 2%
Unknown 49 98%

Demographic breakdown

Readers by professional status Count As %
Researcher 11 22%
Student > Bachelor 7 14%
Student > Master 5 10%
Student > Ph. D. Student 3 6%
Student > Postgraduate 2 4%
Other 6 12%
Unknown 16 32%
Readers by discipline Count As %
Medicine and Dentistry 10 20%
Agricultural and Biological Sciences 5 10%
Pharmacology, Toxicology and Pharmaceutical Science 4 8%
Biochemistry, Genetics and Molecular Biology 4 8%
Business, Management and Accounting 2 4%
Other 6 12%
Unknown 19 38%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 March 2015.
All research outputs
#17,286,645
of 25,374,917 outputs
Outputs from Brazilian Journal of Medical and Biological Research
#743
of 1,254 outputs
Outputs of similar age
#168,910
of 278,918 outputs
Outputs of similar age from Brazilian Journal of Medical and Biological Research
#8
of 20 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. This one is in the 21st percentile – i.e., 21% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,254 research outputs from this source. They receive a mean Attention Score of 4.9. This one is in the 30th percentile – i.e., 30% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 278,918 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 30th percentile – i.e., 30% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 20 others from the same source and published within six weeks on either side of this one. This one is in the 40th percentile – i.e., 40% of its contemporaries scored the same or lower than it.